Abstract:Abstract Background The efficacy of neoadjuvant treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant remains unsatisfactory. This study explored the potential benefits of combining first-generation EGFR-TKI with chemotherapy as a neoadjuvant treatment for patients with stage III-N2 EGFR-mutant non-small cell lung cancer (NSCLC). Patients and Methods The medical records of patients with III-N2 EGFR-mutant NSCLC who received neoadjuvant therapy with EGFR-TKI at Shanghai Chest Hospital from October 2011 to October 2022 were retrospectively reviewed. Patients with stage III-N2 EGFR-mutant NSCLC who received first-generation TKI combined with chemotherapy as neoadjuvant treatment were included in the combination group, and those who received EGFR-TKI monotherapy were included in the monotherapy group. The study assessed the objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, disease-free survival (DFS), overall survival (OS), downstaging rates of pathologic lymph nodes (from stage N2 to N1 or N0), major pathologic response (MPR) rate, pathological complete response (PCR) rate, and safety. Results A total of 74 631 patients with EGFR-mutant NSCLC were screened, and 60 patients were included, 7 of whom did not undergo surgery after neoadjuvant targeted therapy. Of the remaining 53 patients, 15 received first-generation EGFR-TKI combined with chemotherapy as neoadjuvant treatment, and 38 received EGFR-TKI monotherapy. The median follow-up time was 44.12 months. The ORR was 50.0% (9/18) in the combination group and 40.5% (17/42) in the monotherapy group (P = .495). The MPR rate was 20.0% (3/15) and 10.5% (4/38) in the combination and monotherapy groups, respectively (P = .359). No patients achieved PCR in the combination group, while 3 (7.89%) attained PCR in the monotherapy group. The 2 groups did not differ in N2 downstaging rate (P = .459). The median DFS was not reached in the combination group, while it was 23.6 months (95% CI: 8.16-39.02) in the monotherapy group (P = .832). Adverse events observed were consistent with those commonly associated with the 2 treatments. Conclusion Combination therapy with first-generation EGFR-TKI and chemotherapy could be considered a neoadjuvant treatment option for patients with stage III-N2 EGFR-mutant NSCLC, exhibiting acceptable toxicity. However, regarding short-term efficacy, combination therapy did not demonstrate superiority over EGFR-TKI monotherapy. Long-term follow-up is warranted for a more accurate assessment of the DFS and OS.

Intercalated combination of chemotherapy for advanced non-small cell lung cancer patients with secondary drug resistance to epidermal growth factor receptor-tyrosine kinasas inhibitors therapy

Continuing EGFR-TKI in Combination with Super-Selected Arterial Infusion Chemotherapy Beyond RECIST PD for Patients with Advanced EGFR Positive Mutation Non-Small Cell Lung Cancer.

Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival

Systems Assessment of Intercalated Combination of Chemotherapy and EGFR TKIs Versus Chemotherapy or EGFR TKIs Alone in Advanced NSCLC Patients

Combination of EGFR-TKIs with Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients with EGFR Mutation

EGFR-TKIs Plus Chemotherapy Demonstrated Superior Efficacy Than EGFR-TKIs Alone As First-Line Setting in Advanced NSCLC Patients with EGFR Mutation and BIM Deletion Polymorphism.

Superior Efficacy of Immunotherapy‐based Combinations over Monotherapy for EGFR‐mutant Non‐small Cell Lung Cancer Acquired Resistance to EGFR‐TKIs

Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations.

Epidermal Growth Factor Receptor‐tyrosine Kinase Inhibitor Therapy is Effective As First‐line Treatment of Advanced Non‐small‐cell Lung Cancer with Mutated EGFR: A Meta‐analysis from Six Phase III Randomized Controlled Trials

The Efficacy Of Chemotherapy In The Advanced Nsclc Patients Who Failed With The Treatment Of Egfr-Tki

Clinical Studies on Conformal Radiotherapy Combined with Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor in Second-Line Treatment of Non-Small Cell Lung Cancer

The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials

Efficacy of Epidermal Growth Factor Receptor Inhibitors in Combination with Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

The efficacy and safety of EGFR-TKI combined with chemotherapy in NSCLC patients with EGFR co-mutation with other oncogenic alterations.

Clinical Efficacy Of Egfr-Tkis In Combination With Chemotherapy In Patients With Advanced Non-Small Cell Lung Cancer Harboring Egfr Mutations

Study of Gefitinib and Pemetrexed As First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation

Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer

EGFR -TKI Combined with Pemetrexed Versus EGFR -TKI Monotherapy in Advanced EGFR -mutated NSCLC: A Prospective, Randomized, Exploratory Study

Prospective Assessment of Pemetrexed or Pemetrexed Plus Platinum in Combination with Gefitinib or Erlotinib in Patients with Acquired Resistance to Gefitinib or Erlotinib: A Phase II Exploratory and Preliminary Study

Combination of Chemotherapy and Gefitinib As First-Line Treatment for Patients with Advanced Lung Adenocarcinoma and Sensitive Egfr Mutations: A Randomized Controlled Trial

A Phase II Randomized Trial Evaluating Gefitinib Intercalated with Pemetrexed/platinum Chemotherapy or Pemetrexed/platinum Chemotherapy Alone in Unselected Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer